PA
ALNY icon

PharVision Advisers’s Alnylam Pharmaceuticals ALNY Stock Holding History

PharVision Advisers’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-504
Closed -$200K – 119
2025
Q4 		$200K Buy
+504
New +$223K 0.1% 557

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

PharVision Advisers's ALNY Position: Q1 2026 in Review

PharVision Advisers sold out of Alnylam Pharmaceuticals (ALNY) in Q1 2026, closing a stake of 504 shares — an estimated $200K sold.

PharVision Advisers first reported a position in ALNY in Q4 2025 and held it in 1 quarter. The position peaked at $200K in Q4 2025. 793 funds tracked by Wall St. Rank hold ALNY as of Q1 2026.

  • PharVision Advisers reported no remaining Alnylam Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • PharVision Advisers sold 504 Alnylam Pharmaceuticals shares in Q1 2026, an estimated $200K.
  • PharVision Advisers first reported a position in Alnylam Pharmaceuticals in Q4 2025 and held it in 1 quarter.
  • PharVision Advisers's Alnylam Pharmaceuticals position peaked at $200K in Q4 2025.
  • 793 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2026.

Based on PharVision Advisers's 13F filing for Q1 2026, filed 22 Apr 2026.